Fig. 7: Immunity therapy of PMZH. | Nature Communications

Fig. 7: Immunity therapy of PMZH.

From: A bimetallic nanoplatform for STING activation and CRISPR/Cas mediated depletion of the methionine transporter in cancer cells restores anti-tumor immune responses

Fig. 7: Immunity therapy of PMZH.

a Flow cytometry analysis of DCs (gating on CD11c+) infiltrated after treatment with different formulations. Populations of b CD8+ and c CD4+T cells in 4T1 tumor tissues after different treatment. Cytokine expression levels of d TNF-α and e IL-6 in serum were analyzed by Elisa kit after different treatments. f The IFN-β expression in tumors treated with different preparations was detected by qPCR. Data were presented as mean ± SD (n = 4 independent samples) in a–f. P values were assessed using Student’s t test (two-tailed). g Immunoblotting analysis of STING pathway-related protein levels in tumor samples from various treatment groups. h Semi-quantitative analysis of p-TBK1 and IFN-β expression. n = 3 independent samples in h. Data were presented as mean ± SD. Source data are provided as a Source Data file.

Back to article page